Page 1 | Search Results | Hematology, ASH Education Program

1-20 of 5096

Sort by

Sort Order Select

Journal Articles

Hodgkin lymphoma treatment for older persons in the modern era

Andrew M. Evens, Marshall McKenna, Yun Kyoung Ryu Tiger, Jenica N. Upshaw

Hematology Am Soc Hematol Educ Program (2023) 2023 (1): 483–499.

https://doi.org/10.1182/hematology.2023000449

Published: 2023

Includes: Supplemental data

Journal Articles

Current use of CAR T cells to treat multiple myeloma

Ross S. Firestone, Sham Mailankody

Hematology Am Soc Hematol Educ Program (2023) 2023 (1): 340–347.

https://doi.org/10.1182/hematology.2023000434

Published: 2023

Journal Articles

Current use of bispecific antibodies to treat multiple myeloma

Holly Lee, Paola Neri, Nizar J. Bahlis

Hematology Am Soc Hematol Educ Program (2023) 2023 (1): 332–339.

https://doi.org/10.1182/hematology.2023000433

Published: 2023

Journal Articles

Should posttransplant cyclophosphamide be considered standard of care for pediatric transplantation of acute leukemia?

Erin E. Doherty, Robert A. Krance

Hematology Am Soc Hematol Educ Program (2023) 2023 (1): 171–174.

https://doi.org/10.1182/hematology.2023000522

Published: 2023

Journal Articles

Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies

Idoroenyi Amanam, Salman Otoukesh, Monzr M. Al Malki, Amandeep Salhotra

Hematology Am Soc Hematol Educ Program (2023) 2023 (1): 164–170.

https://doi.org/10.1182/hematology.2023000427

Published: 2023

Journal Articles

Clinical manifestations of telomere biology disorders in adults

Marena R. Niewisch, Fabian Beier, Sharon A. Savage

Hematology Am Soc Hematol Educ Program (2023) 2023 (1): 563–572.

https://doi.org/10.1182/hematology.2023000490

Published: 2023

Journal Articles

Management of Fanconi anemia beyond childhood

Timothy S. Olson

Hematology Am Soc Hematol Educ Program (2023) 2023 (1): 556–562.

https://doi.org/10.1182/hematology.2023000489

Published: 2023

Journal Articles

Barriers to accessing cellular therapy for patients receiving care in community practices

Chijioke Nze, Christopher R. Flowers

Hematology Am Soc Hematol Educ Program (2023) 2023 (1): 382–385.

https://doi.org/10.1182/hematology.2023000518

Published: 2023

Journal Articles

Too many white cells—TAM, JMML, or something else?

Alexandra Satty, Elliot Stieglitz, Nicole Kucine

Hematology Am Soc Hematol Educ Program (2023) 2023 (1): 37–42.

https://doi.org/10.1182/hematology.2023000464

Published: 2023

Journal Articles

T-cell lymphopenia in frequent volunteer platelet donors

Richard M. Kaufman

Hematology Am Soc Hematol Educ Program (2023) 2023 (1): 305–310.

https://doi.org/10.1182/hematology.2023000484

Published: 2023

Journal Articles

Improving long-term outcomes with intensive induction chemotherapy for patients with AML

Christoph Röllig

Hematology Am Soc Hematol Educ Program (2023) 2023 (1): 175–185.

https://doi.org/10.1182/hematology.2023000504

Published: 2023

Journal Articles

Planning GvHD preemptive therapy: risk factors, biomarkers, and prognostic scores

Jacob Rozmus, John E. Levine, Kirk R. Schultz

Hematology Am Soc Hematol Educ Program (2023) 2023 (1): 149–154.

https://doi.org/10.1182/hematology.2023000425

Published: 2023

Journal Articles

Langerhans cell histiocytosis: promises and caveats of targeted therapies in high-risk and CNS disease

Oussama Abla

Hematology Am Soc Hematol Educ Program (2023) 2023 (1): 386–395.

https://doi.org/10.1182/hematology.2023000439

Published: 2023

Journal Articles

How to manage hemostasis in patients with liver disease during interventions

Lara N. Roberts

Hematology Am Soc Hematol Educ Program (2023) 2023 (1): 274–280.

https://doi.org/10.1182/hematology.2023000480

Published: 2023

Journal Articles

How to assess hemostasis in patients with severe liver disease

Ton Lisman

Hematology Am Soc Hematol Educ Program (2023) 2023 (1): 267–273.

https://doi.org/10.1182/hematology.2023000479

Published: 2023

Journal Articles

Immunotherapy of acquired hemophilia A

Andreas Tiede

Hematology Am Soc Hematol Educ Program (2023) 2023 (1): 19–23.

https://doi.org/10.1182/hematology.2023000461

Published: 2023

Journal Articles

The approach of HMA plus VEN with or without BMT for all patients with AML

Heather J. Male, Tara L. Lin

Hematology Am Soc Hematol Educ Program (2023) 2023 (1): 186–191.

https://doi.org/10.1182/hematology.2023000428

Published: 2023

Journal Articles

Novel approaches to acute graft-versus-host disease prevention

Benjamin Watkins, Muna Qayed

Hematology Am Soc Hematol Educ Program (2023) 2023 (1): 155–163.

https://doi.org/10.1182/hematology.2023000426

Published: 2023

Journal Articles

Accelerated-phase CML: de novo and transformed

Naranie Shanmuganathan, Timothy P. Hughes

Hematology Am Soc Hematol Educ Program (2023) 2023 (1): 459–468.

https://doi.org/10.1182/hematology.2023000446

Published: 2023

Journal Articles

Prevention, diagnosis, and management of PE and DVT in pregnant women

Barry Kevane, Fionnuala Ní Áinle

Hematology Am Soc Hematol Educ Program (2023) 2023 (1): 237–247.

https://doi.org/10.1182/hematology.2023000476

Published: 2023

NARROW

Hodgkin lymphoma treatment for older persons in the modern era

Current use of CAR T cells to treat multiple myeloma

Current use of bispecific antibodies to treat multiple myeloma

Should posttransplant cyclophosphamide be considered standard of care for pediatric transplantation of acute leukemia?

Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies

Clinical manifestations of telomere biology disorders in adults

Management of Fanconi anemia beyond childhood

Barriers to accessing cellular therapy for patients receiving care in community practices

Too many white cells—TAM, JMML, or something else?

T-cell lymphopenia in frequent volunteer platelet donors

Improving long-term outcomes with intensive induction chemotherapy for patients with AML

Planning GvHD preemptive therapy: risk factors, biomarkers, and prognostic scores

Langerhans cell histiocytosis: promises and caveats of targeted therapies in high-risk and CNS disease

How to manage hemostasis in patients with liver disease during interventions

How to assess hemostasis in patients with severe liver disease

Immunotherapy of acquired hemophilia A

The approach of HMA plus VEN with or without BMT for all patients with AML

Novel approaches to acute graft-versus-host disease prevention

Accelerated-phase CML: de novo and transformed

Prevention, diagnosis, and management of PE and DVT in pregnant women

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only